A new beclomethasone dipropionate multidose powder inhaler in the treatment of bronchial asthma. 1998

M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
Department of Pulmonary Diseases, Tampere University Central Hospital, Tampere, Finland.

The clinical efficacy, tolerability and acceptability of a new multidose powder inhaler (MDPI) containing beclomethasone dipropionate (BDP) were compared with those of a BDP aerosol administered with a large volume spacer (MDI-spacer) among adult asthmatics currently receiving from 500 to 1,000 microgram/day of an inhaled corticosteroid. During the study, the dosage of BDP from both devices was 400 microgram twice daily. Ninety-one patients were randomized to the MDPI group and 42 to the MDI-spacer group. The trial was performed as an open, randomized, parallel group multicenter study. The duration of the treatment period was 12 weeks, and the study was preceded by a 2-week run-in period. During the run-in period, the mean morning peak expiratory flow (PEF) was 487 and 466 1/min in the MDPI and MDI-spacer groups, respectively. After the 12-week treatment, the morning PEF was 491 1/min in the MDPI group and 463 1/min in the MDI-spacer group. The evening values were 500 and 479 1/min during the run-in period and 496 and 476 1/min after the 12-week treatment, respectively. Asthma symptom scores and the use of rescue medication were low in both groups, indicating good efficacy of the preparations tested. The median dose of histamine required to decrease forced expiratory volume in 1 s by 15% increased during the study from 800 to 1,098 microgram in the MDPI group and from 795 to 960 microgram in the MDI-spacer group. The most frequent adverse events in both groups were hoarseness and sore throat. There were no statistically significant differences between the treatment groups in serum cortisol values or in the number of patients with thrush. Seventy-two percent of the patients regarded the MDPI easier to use while 95% considered it more portable. Over 80% of the patients felt that the MDPI was also easier to clean and as easy or easier to learn to use than the MDI-spacer. To conclude, the novel powder inhaler is well tolerated and at least equally effective as the conventional MDI-spacer combination in the treatment of asthma with BDP. However, in everyday use, patients clearly favored the powder inhaler.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D010366 Peak Expiratory Flow Rate Measurement of the maximum rate of airflow attained during a FORCED VITAL CAPACITY determination. Common abbreviations are PEFR and PFR. Expiratory Peak Flow Rate,Flow Rate, Peak Expiratory,PEFR
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005387 Finland A country in northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. The capital is Helsinki. Aland Islands,Åland Islands
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 1985, The Journal of international medical research,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 2000, Respiration; international review of thoracic diseases,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 1998, Clinical drug investigation,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
September 1978, Lancet (London, England),
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 1975, Postgraduate medical journal,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
July 1974, Ugeskrift for laeger,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
August 1976, The Journal of allergy and clinical immunology,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 1977, Allergologia et immunopathologia,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
January 1977, Journal of medicine,
M M Nieminen, and P Vidgren, and J Kokkarinen, and K Laasonen, and K Liippo, and A Lindqvist, and M Paananen, and A Poukkula, and E Ruotsalainen, and E Salomaa, and A Sovijärvi, and T Söderblom, and M Silvasti, and M Vidgren, and L A Laitinen
April 2008, Expert review of respiratory medicine,
Copied contents to your clipboard!